Exploratory transcriptomic analysis suggests candidate genes associated with loss of response to ustekinumab in Crohn’s disease
Frontiers in Genetics · 22.05.2026 · 17
DOI: 10.3389/fgene.2026.1812181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Genetics, online erschienen am 22.05.2026. Verfasst von Jiayi Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Despite the favorable safety and efficacy of ustekinumab in clinical practice for Crohn’s disease, a subset of Crohn’s disease patients still experience loss of response to this treatment. This study was thus conducted to investigate the differential gene expression underlying ustekinumab loss of response in Crohn’s disease patients.
Methods
This prospective study, grouped by response to ustekinumab, collected peripheral blood mononuclear cells from refractory moderate-to-severe adult Crohn’s disease patients (8 vs. 9) who were admitted to the Second Affiliated Hospital of Guangzhou Medical University and received initial ustekinumab treatment between January 2024 and June 2025 for RNA sequencing. For exploratory pathway analysis, differentially expressed genes identified by DESeq2 using exploratory thresholds (|FC| > 1.5, P < 0.05) were subjected to GO and KEGG enrichment, WGCNA, and PPI network analyses. Additionally, another 16 patients were included for the preliminary validation of candidate genes by qPCR. Furthermore, we conducted a clinical influence factor analysis on 81 patients who had already received medication.
Results
RNA sequencing identified 510 differentially expressed genes between ustekinumab responders and non-responders. Trait association analysis showed that the cyan module was the module most strongly associated with both ustekinumab non-response and stricturing behavior, consistent with the independent influence of stricturing behavior identified in the retrospective clinical study. This module was enriched in platelet activation, neutrophil extracellular trap formation, and focal adhesion (KEGG), as well as coagulation and platelet aggregation (GO). Among the 10 candidate genes selected for validation, FFAR2, ITGA2B, SOCS3, and KCNJ15 exhibited statistically significant differential expression.
Conclusion
Our findings suggest that loss of response may be potentially associated with pro-inflammatory pathways independent of the drug’s action pathways, as well as a “pro-fibrotic immune microenvironment” linked to intestinal strictures. Additionally, preliminary validation indicated that FFAR2, ITGA2B, SOCS3, and KCNJ15 may provide new perspectives for candidate differentially expressed genes associated with ustekinumab loss of response.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Second Affiliated Hospital, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.
Zitieren
APA
Lin, J., Xie, T., Zhong, J., Tu, Y., Xiao, C., Huang, X., & Wang, Y. (2026). Exploratory transcriptomic analysis suggests candidate genes associated with loss of response to ustekinumab in Crohn’s disease. Frontiers in Genetics, 17. https://doi.org/10.3389/fgene.2026.1812181
Vancouver
Lin J, Xie T, Zhong J, Tu Y, Xiao C, Huang X, et al. Exploratory transcriptomic analysis suggests candidate genes associated with loss of response to ustekinumab in Crohn’s disease. Frontiers in Genetics. 2026;17. doi:10.3389/fgene.2026.1812181
BibTeX
@article{Lin2026,
author = {Lin, Jiayi and Xie, Tingting and Zhong, Jiahao and Tu, Yanmei and Xiao, Chang and Huang, Xueying and Wang, Yixi},
title = {Exploratory transcriptomic analysis suggests candidate genes associated with loss of response to ustekinumab in Crohn’s disease},
journal = {Frontiers in Genetics},
year = {2026},
volume = {17},
doi = {10.3389/fgene.2026.1812181}
}
EUVIMED